New retrospective data highlighting the Precision Spectra Spinal Cord Stimulator (Boston Scientific) System demonstrate the device provided highly significant pain relief three months after implantation. The results were presented at the North American Neuromodulation Society (NANS) 17th annual meeting in Las Vegas, USA (5–8 December).
Precision Spectra is the first spinal cord stimulation system designed to improve pain relief, according to a press release. It uses the Illumina 3D Software, a three dimensional anatomy-driven computer model. By providing 32 contacts the Precision Spectra System offers more coverage of the spinal cord for the management of chronic pain.
The retrospective study of up to 213 consecutive patients at 13 centres focused on patients with chronic pain who were treated with the Precision Spectra. Results include:
- A 94% spinal cord stimulation trial therapy success rate (n=213)
- A highly significant reduction in pain from an average baseline score of 7.8, on a 10-point scale, to an average score of 3.2 at three months post implant (in the patients who have reached the three-month follow up, n=113)
- Early results indicate improvements in function, including walking and sleeping, in addition to reductions in opioid use and disability.
“The primary objective of spinal cord stimulation is pain relief,” said Salim Hayek, chief, Division of Pain Medicine at University Hospitals of Cleveland, USA. “These initial results indicate that the Precision Spectra System is effectively reducing pain in these real-world patients at three months post implant.”
“Boston Scientific is committed to advancing science to improve pain relief,” said Maulik Nanavaty, president, Neuromodulation, Boston Scientific. “These data are very promising and we look forward to the results of our ongoing clinical programs to demonstrate the long term benefits of the Precision Spectra.”
